ORIC Stock Recent News

ORIC LATEST HEADLINES

ORIC Stock News Image - zacks.com

From a technical perspective, Oric Pharmaceuticals, Inc. (ORIC) is looking like an interesting pick, as it just reached a key level of support. ORIC's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

zacks.com 2025 Jul 15
ORIC Stock News Image - zacks.com

Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com 2025 Jul 11
ORIC Stock News Image - globenewswire.com

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the “Grant Date”), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new non-executive employee who began their employment with ORIC in June 2025.

globenewswire.com 2025 Jul 03
ORIC Stock News Image - zacks.com

Oric Pharmaceuticals (ORIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com 2025 Jun 19
ORIC Stock News Image - zacks.com

The consensus price target hints at a 105% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

zacks.com 2025 Jun 19
ORIC Stock News Image - zacks.com

Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com 2025 Jun 13
ORIC Stock News Image - globenewswire.com

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the “Grant Date”), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025.

globenewswire.com 2025 Jun 06
ORIC Stock News Image - zacks.com

The consensus price target hints at a 131.3% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

zacks.com 2025 Jun 02
ORIC Stock News Image - zacks.com

ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.

zacks.com 2025 May 29
ORIC Stock News Image - benzinga.com

ORIC Pharmaceuticals Inc. ORIC released preliminary efficacy and safety data on Wednesday from its ongoing Phase 1b trial of once daily ORIC-944 in combination with androgen receptor (AR) inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC).

benzinga.com 2025 May 29
10 of 40